KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) EBITDA Margin (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed EBITDA Margin for 4 consecutive years, with 516.51% as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, EBITDA Margin fell 37463.0% year-over-year to 516.51%, compared with a TTM value of 385.87% through Dec 2023, down 41818.0%, and an annual FY2024 reading of 574.05%, down 18818.0% over the prior year.
  • EBITDA Margin was 516.51% for Q4 2023 at AbCellera Biologics, down from 426.96% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 57.82% in Q1 2021 and bottomed at 516.51% in Q4 2023.
  • Average EBITDA Margin over 4 years is 125.0%, with a median of 22.0% recorded in 2020.
  • The sharpest move saw EBITDA Margin surged 44056bps in 2022, then crashed -45195bps in 2023.
  • Year by year, EBITDA Margin stood at 56.28% in 2020, then dropped by -24bps to 42.76% in 2021, then tumbled by -432bps to 141.88% in 2022, then plummeted by -264bps to 516.51% in 2023.
  • Business Quant data shows EBITDA Margin for ABCL at 516.51% in Q4 2023, 426.96% in Q3 2023, and 302.37% in Q2 2023.